Shanghai’s New Chapter

How a new Shanghai exchange board could compete for biotech listings

A planned science and technology innovation board on the Shanghai Stock Exchange could provide another route to public funding for Chinese life science companies within a matter of months. While the exchange may not compete with the Hong Kong stock exchange and NASDAQ for global biotech listings anytime soon, it may be a destination for companies that have not been able to access those

Read the full 647 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers